Tumour necrosis factor- inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis: a systematic review and economic evaluation -

Tumour necrosis factor- inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis: a systematic review and economic evaluation
Information type: Systematic reviews
Source: National Institute for Health Research
Specialities: Musculo-skeletal disorders
Summary
A review of 28 RCTs which concluded that in both ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nr-AxSpA) anti-TNFs are clinically effective, although more so in AS than in nr-AxSpA. Anti-TNFs may be an effective use of NHS resources.
UKMi comment
This review forms the basis for the NICE technology appraisal on “Ankylosing spondylitis and axial spondyloarthritis (non-radiographic) - adalimumab, etanercept, infliximab and golimumab (TA383).
Related links: Link to NICE TA 383